Bicycle Therapeutics plc
BCYC
$7.12
$0.020.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -68.81% | -48.91% | -30.44% | -50.00% | -17.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -68.81% | -48.91% | -30.44% | -50.00% | -17.86% |
| Cost of Revenue | 77.31% | 73.83% | -218.89% | 19.59% | 7.85% |
| Gross Profit | -121.87% | -252.52% | 248.90% | -30.94% | -19.23% |
| SG&A Expenses | 15.95% | 25.19% | 81.96% | 16.11% | -8.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.84% | 56.46% | 19.82% | 18.47% | 2.75% |
| Operating Income | -85.65% | -121.35% | -24.76% | -25.69% | -8.20% |
| Income Before Tax | -99.47% | -129.78% | -8.52% | -13.91% | 7.94% |
| Income Tax Expenses | -300.87% | -210.57% | -438.13% | -251.76% | 122.24% |
| Earnings from Continuing Operations | -98.31% | -128.72% | -5.61% | -1.81% | 6.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.31% | -128.72% | -5.61% | -1.81% | 6.55% |
| EBIT | -85.65% | -121.35% | -24.76% | -25.69% | -8.20% |
| EBITDA | -88.65% | -128.13% | -25.44% | -25.59% | -8.54% |
| EPS Basic | -48.90% | -40.68% | 35.13% | 41.59% | 45.74% |
| Normalized Basic EPS | -49.75% | -41.35% | 27.70% | 35.81% | 46.54% |
| EPS Diluted | -48.90% | -40.68% | 35.13% | 41.59% | 45.74% |
| Normalized Diluted EPS | -49.75% | -41.35% | 27.70% | 35.81% | 46.54% |
| Average Basic Shares Outstanding | 33.20% | 62.59% | 62.78% | 74.32% | 72.21% |
| Average Diluted Shares Outstanding | 33.20% | 62.59% | 62.78% | 74.32% | 72.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |